TGTX - TG Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Morrisville,
United States
Type: Equity
TGTX price evolution
TGTX
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $84.2 | $76.77 | $94.22 | $152.18 |
| Short term investments | $134.34 | $134.31 | $124.58 | $78.26 |
| Net receivables | $83.61 | $64.98 | $51.09 | $39.32 |
| Inventory | $81.24 | $77.72 | $39.82 | $33.55 |
| Total current assets | $389.15 | $360.58 | $317.94 | $319.11 |
| Long term investments | $0.95 | $1.32 | ||
| Property, plant & equipment | $7.66 | $9.33 | $9.56 | $9.87 |
| Goodwill & intangible assets | $0.8 | $0.8 | $0.8 | |
| Total noncurrent assets | $12.06 | $12.74 | $11.64 | $11.95 |
| Total investments | $135.29 | $135.63 | $124.58 | $78.26 |
| Total assets | $401.21 | $373.32 | $329.59 | $331.07 |
| Current liabilities | ||||
| Accounts payable | $93.47 | $87.27 | $38.47 | $39.74 |
| Deferred revenue | $7.12 | $6.62 | $6.02 | $7.09 |
| Short long term debt | ||||
| Total current liabilities | $108.66 | $99.68 | $53.72 | $57.68 |
| Long term debt | $111.23 | $110.29 | $109.35 | $108.43 |
| Total noncurrent liabilities | $114.97 | $113.53 | $115.36 | $108.62 |
| Total debt | $111.23 | $110.29 | $109.35 | $108.43 |
| Total liabilities | $223.64 | $213.21 | $169.09 | $166.3 |
| Shareholders' equity | ||||
| Retained earnings | -$1556.4 | -$1525.07 | -$1514.36 | -$1499.94 |
| Other shareholder equity | ||||
| Total shareholder equity | $177.57 | $160.11 | $160.5 | $164.77 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $94.22 | $103.58 | $300.15 | $554.7 |
| Short term investments | $124.58 | $59.37 | $15.88 | $51.99 |
| Net receivables | $51.09 | $1.39 | ||
| Inventory | $39.82 | |||
| Total current assets | $317.94 | $168.27 | $330.96 | $611.74 |
| Long term investments | $12.4 | $35.53 | ||
| Property, plant & equipment | $9.56 | $10.82 | $11.07 | $11.84 |
| Goodwill & intangible assets | $0.8 | $0.8 | $0.8 | $0.8 |
| Total noncurrent assets | $11.64 | $25.3 | $48.66 | $13.9 |
| Total investments | $124.58 | $71.78 | $51.41 | $51.99 |
| Total assets | $329.59 | $193.57 | $379.63 | $625.64 |
| Current liabilities | ||||
| Accounts payable | $38.47 | $42.02 | $51.29 | $37.01 |
| Deferred revenue | $6.02 | $0.3 | $0.46 | $0.61 |
| Short long term debt | $0.97 | $22.18 | ||
| Total current liabilities | $53.72 | $53.2 | $65.38 | $87.55 |
| Long term debt | $109.35 | $81.48 | $76.64 | $18.13 |
| Total noncurrent liabilities | $115.36 | $81.78 | $77.09 | $18.74 |
| Total debt | $109.35 | $81.48 | $77.61 | $40.31 |
| Total liabilities | $169.09 | $134.99 | $142.48 | $106.29 |
| Shareholders' equity | ||||
| Retained earnings | -$1514.36 | -$1527.03 | -$1328.7 | -$980.6 |
| Other shareholder equity | ||||
| Total shareholder equity | $160.5 | $58.59 | $237.15 | $519.35 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $73.47 | $63.47 | $43.97 | $165.81 |
| Cost of revenue | $8.3 | $5.44 | $7.85 | $3.51 |
| Gross Profit | $65.16 | $58.03 | $36.12 | $162.31 |
| Operating activities | ||||
| Research & development | $17.56 | $32.72 | $17.45 | $14.75 |
| Selling, general & administrative | $38.79 | $34.58 | $31.15 | $32.77 |
| Total operating expenses | $56.35 | $67.3 | $48.6 | $47.52 |
| Operating income | $8.82 | -$9.27 | -$12.48 | $114.78 |
| Income from continuing operations | ||||
| EBIT | $10.53 | -$8.39 | -$11.6 | $117.64 |
| Income tax expense | -$0.33 | $0.03 | $0.39 | |
| Interest expense | $3.98 | $2.29 | $2.43 | $3.71 |
| Net income | ||||
| Net income | $6.88 | -$10.71 | -$14.42 | $113.93 |
| Income (for common shares) | $6.88 | -$10.71 | -$14.42 | $113.93 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $233.66 | $2.79 | $6.69 | $0.15 |
| Cost of revenue | $14.13 | $0.27 | $0.79 | |
| Gross Profit | $219.53 | $2.52 | $5.9 | $0.15 |
| Operating activities | ||||
| Research & development | $76.19 | $125.35 | $222.58 | $165.9 |
| Selling, general & administrative | $122.71 | $70.01 | $128.09 | $107.85 |
| Total operating expenses | $198.9 | $195.36 | $350.67 | $273.75 |
| Operating income | $20.63 | -$192.84 | -$344.77 | -$273.59 |
| Income from continuing operations | ||||
| EBIT | $25.68 | -$188.14 | -$342.46 | -$273.05 |
| Income tax expense | $0.39 | |||
| Interest expense | $12.62 | $10.19 | $5.64 | $6.33 |
| Net income | ||||
| Net income | $12.67 | -$198.34 | -$348.1 | -$279.38 |
| Income (for common shares) | $12.67 | -$198.34 | -$348.1 | -$279.38 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | $6.88 | -$10.71 | -$14.42 | $113.93 |
| Operating activities | ||||
| Depreciation | $0.02 | $0.03 | $0.04 | $0.07 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $9.48 | $9.34 | $9.38 | $9.18 |
| Total cash flows from operations | $5.54 | -$8.21 | -$13.21 | $83.7 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | $1.76 | -$9.26 | -$44.76 | -$30.23 |
| Total cash flows from investing | $1.76 | -$9.26 | -$44.76 | -$30.23 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.14 | $0.01 | -$0 | $0.42 |
| Net borrowings | ||||
| Total cash flows from financing | $0.14 | $0.01 | -$0 | $0.42 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $7.44 | -$17.45 | -$57.97 | $53.9 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $12.67 | -$198.34 | -$348.1 | -$279.38 |
| Operating activities | ||||
| Depreciation | $0.21 | $0.3 | $0.28 | $0.16 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $37.93 | $19.18 | $61.27 | $80.29 |
| Total cash flows from operations | -$31.41 | -$176.17 | -$295.63 | -$214.51 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0.4 | -$0.36 | |
| Investments | -$50.65 | -$20 | $0.07 | -$24.15 |
| Total cash flows from investing | -$50.65 | -$20.01 | -$0.33 | -$24.51 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $47.83 | $0.58 | $2.44 | $679.83 |
| Net borrowings | $25 | -$0.97 | $40 | |
| Total cash flows from financing | $72.7 | -$0.39 | $41.42 | $679.83 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$9.36 | -$196.57 | -$254.55 | $440.81 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $346.73M |
|---|---|
| EBITDA | $108.34M |
| EBIT | $108.19M |
| Net Income | $95.69M |
| Revenue Q/Q | 357.05% |
| Revenue Y/Y | 1.34K% |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | 26.67% |
| ROE | 57.73% |
| Debt/Equity | 1.05 |
|---|---|
| Net debt/EBITDA | 1.29 |
| Current ratio | 3.58 |
| Quick ratio | 2.83 |